- Sinopharm’s FY net income surpassed estimates, coming in at 9.05 billion yuan, a year-on-year increase of 6.2%.
- The company’s revenue was 596.6 billion yuan, marking a year-on-year growth of 8.1%. This was slightly below the estimated 606.63 billion yuan.
- Operating profit stood at 20.21 billion yuan, a year-on-year decrease of 1.9%. This was lower than the estimated 23.07 billion yuan.
- The final dividend per share was 87 RMB cents, up from 82 RMB cents compared to the previous year.
- Investment sentiment towards Sinopharm is positive with 18 buys, 2 holds, and no sells.
- The comparisons to past results are based on values reported by the company’s original disclosures.
Sinopharm Group Co Ltd H on Smartkarma
On Smartkarma, an independent investment research network, top independent analysts like Xinyao (Criss) Wang are publishing research on companies like Sinopharm Group Co Ltd H. In her recent report, titled “Sinopharm Group (1099.HK) – Performance Pressure May Continue Until 2024H1,” Wang discusses the company’s weaker-than-expected performance in 23Q1-Q3, which has dragged down their full-year growth. She notes that single-digit growth seems inevitable and the outlook for 2024H1 is likely to remain under pressure. The main reason for this underperformance is attributed to the anti-corruption campaign, which has caused significant changes in fundamentals and policy end. However, Wang predicts that the impact of anti-corruption will weaken in Q4 and the traditional distribution business will recover, leading to a better performance in 23Q4. Despite this, she still expects 23H2 performance to be worse than 23H1 and has lowered her forecast for 2023, with revenue and net profit expected to achieve only single-digit growth. Wang also points out that due to the high base in 23H1, growth in 24H1 could still be under pressure.
A look at Sinopharm Group Co Ltd H Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Sinopharm Group Co Ltd H, a leading pharmacy distribution company, is poised for long-term success according to the Smartkarma Smart Scores. With a score of 5 for both Value and Dividend, the company is well-positioned to provide strong returns for its investors. Additionally, with a score of 4 for Growth, Sinopharm Group Co Ltd H is expected to continue expanding its reach and market share in the pharmacy industry.
However, the company may face challenges in terms of Resilience, with a score of 2. This suggests that Sinopharm Group Co Ltd H may be more susceptible to economic downturns or disruptions in the market. Nonetheless, with a score of 3 for Momentum, the company is expected to maintain a steady pace of growth and adapt to changing market conditions. Overall, Sinopharm Group Co Ltd H is a well-rounded company with a strong outlook for the future.
Summary: Sinopharm Group Co Ltd is a pharmacy distribution company with a diversified portfolio of pharmacy enterprise groups. According to the Smartkarma Smart Scores, the company has a strong overall outlook, with high scores in Value, Dividend, and Growth. While there may be some concerns regarding Resilience, Sinopharm Group Co Ltd H is expected to maintain its momentum and continue to thrive in the long-term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
